| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Saccomano Nicholas A | President and CEO, Director | C/O ONKURE THERAPEUTICS, INC., 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER | /s/ Rogan Nunn, by power of attorney | 25 Jun 2025 | 0001609284 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OKUR | Class A Common Stock | Sale | $210 | -88 | -2.4% | $2.38 | 3,594 | 23 Jun 2025 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan. |
| F2 | This transaction was executed in multiple trades at prices ranging from $2.33 to $2.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F3 | Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |